IRB - Cerbios-Pharma SA

Cerbios and IRB collaborate on developing antibodies targeted at Leukemia cells

LUGANO, October 2nd, 2018 • The Institute for Research in Biomedicine (IRB-USI, Bellinzona, www.irb.ch), active in human immunology research, and Cerbios-Pharma SA (Barbengo, Lugano), a company active in developing and producing active pharmaceutical ingredients (API), have started collaborating to develop Antibodies’ derivatives to treat Acute Myeloid Leukemia (AML), which makes it possible to target leukemia cells…

USA Ambassador visit to Cerbios-Pharma SA

Lugano/Bern, September 7, 2018 • On September 7, Cerbios was honored by the visit of the US Ambassador to Switzerland and Liechtenstein, Edward McMullen Jr. Aim of the visit of the Ambassador was to meet Cerbios’ top management and shareholder in order to have a better view and understanding of Cerbios’ ongoing and future activities in the…

FDA - Cerbios-Pharma SA

Cerbios successfully passes a general FDA cGMP inspection

LUGANO, April 17th, 2018 • It is with pleasure that we announce that on Friday the 27th of April 2018, Cerbios-Pharma SA (from now on CERBIOS) successfully passed a general FDA GMP inspection. Originally, the inspection was scheduled to last five days. Due to the excellent results, the inspector decided to close the audit in the middle of…